
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.

Nicola A. Hanania, MD, MS, is an associate professor of medicine in the section of pulmonary and critical care medicine and director of the American Lung Association Airways Clinical Research Center (ACRC) at the Baylor College of Medicine.

Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.

Timely dupilumab initiation after a severe asthma exacerbation lowered costs vs delayed treatment, ERS 2026 data show.